Evidence map›Paper›PMID 35654824›Full record

ArticleBone marrow transplantation2022

Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation.

Aurélien Sutra Del Galy, Adrien Rousseau, Antoine Capes, David Michonneau, Marie Robin, Flore Sicre de Fontbrune, Aliénor Xhaard, Camilla Frieri, Lionel Adès, Emmanuel Raffoux and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Managing Survivorship after Hematopoietic Cell Transplantation.Current hematologic malignancy reports · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Aurélien Sutra Del GalyHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.
Adrien Rousseau *Hematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.ORCID http://orcid.org/0000-0001-8708-1664
Antoine Capes *Hematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.
David MichonneauHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.ORCID http://orcid.org/0000-0003-4553-3065
Marie RobinHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.ORCID http://orcid.org/0000-0003-1388-9876
Flore Sicre de FontbruneHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.
Aliénor XhaardHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.
Camilla FrieriHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.
Lionel AdèsHematology/Senior, AP-HP Hospital Saint Louis, Paris, France.ORCID http://orcid.org/0000-0002-9020-8766
Emmanuel RaffouxHematology/Adult, AP-HP Hospital Saint Louis, Paris, France.
Chantal HimberlinHematology, CHRU Reims, Reims, France.
Mathilde BaudetCardiology, AP-HP Hospital Saint Louis, Paris, France.
Régis Peffault de LatourHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France.
Gérard SociéHematology/Transplantation, AP-HP Hospital Saint Louis, Paris, France. gerard.socie@aphp.fr.ORCID http://orcid.org/0000-0002-2114-7533
Assistance Publique – Hôpitaux de Paris · FRInserm · FRCentre Hospitalier Universitaire de Reims · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduced intensity conditionings (RIC) before after allogeneic hematopoietic stem cell transplantation (HSCT) allow older or unfit patients of being transplanted, but survival expectancy and burden of late complications are poorly described in this setting. All patients (N = 456) who were alive and relapse-free 2 years after HSCT following RIC were included. Cumulative incidences (CI), standardized incidence, or mortality, ratio (SIR or SMR), and competing risk models were used. The 10-year CIs of relapse and non-relapse mortality incidences were 13.9 and 13.4%, respectively. Seventy-eight patients died, late relapse being the most frequent cause of death leading to a SMR of 6.38 (95% CI, 5.1-8.0; p < 0.001). Among non-relapsing patients (n = 412), 30 died (SMR 4.38; 95% CI, 3.3-5.8: p < 0.001). A total of 37 patients developed 41 SM leading to a 10-year cumulative incidence of 12.9%, and a significant SIR relative to the general population (1.4). Finally, we found high CI of cardiovascular (CVC) and venous thromboembolic complications (VTE) (10-year CI; 15.1% and 11.7%, respectively). Older age was the only significant risk factor for CVC and VTE in multivariable analysis. In conclusion, with life expectancy rate of 70%, late survivors after RIC warrants long-term follow-up and active intervention on averting cardiovascular disease and screening cancers.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationVenous ThromboembolismHumansLife ExpectancyRecurrenceRetrospective StudiesTransplantation ConditioningTransplantation, Homologous

Identifiers

PMID35654824
OpenAlexW4281619681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.